NDA 021742 · Allergan
Bystolic
Nebivolol Hydrochloride · Oral
NovelLast checked: Nov 20, 2026Latest source record: Jun 16, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Dec 17, 2007
Approved uses
2
Original approval plus efficacy supplements
Registered trials
116
24 Phase 3, 7 recruiting
FAERS reports
17,999
9,157 serious, 861 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 1, 2024.
1. INDICATIONS AND USAGE BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension BYSTOLIC is indicated for the treatment of hypertension, to lower blood pressure [see Clinical Studies ( 14.1 )]. BYSTOLIC may be used alone or in combination with other antihypertensive agents [see Drug Interactions ( 7 )]. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BYSTOLIC. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the...
Mechanism: The mechanism of action of the antihypertensive response of BYSTOLIC has not been definitively established. Possible factors that may be involved include: (1) decreased heart rate, (2) decreased myocardial contractility, (3) diminution of tonic sympathetic outflow to the periphery from cerebral vasomotor centers, (4) suppression of renin activity and (5) vasodilation and decreased peripheral vascular resistance.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 19, 2010 Supplement 7 · Efficacy LetterLabel
- Dec 17, 2007 Original approval · Type 1 - New Molecular Entity NovelReviewLetter
4 products under this application
- BYSTOLIC · NEBIVOLOL HYDROCHLORIDE EQ 5MG BASE · TABLET, ORAL · Prescription · TE AB
- BYSTOLIC · NEBIVOLOL HYDROCHLORIDE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
- BYSTOLIC · NEBIVOLOL HYDROCHLORIDE EQ 2.5MG BASE · TABLET, ORAL · Prescription · TE AB
- BYSTOLIC · NEBIVOLOL HYDROCHLORIDE EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Nebivolol" as an intervention, any sponsor and status, largest first.
- TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"Pivotal-lookingCompleted
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIAcademic, hospital or other
NCT03596385 · 8,505 participants · Start Oct 31, 2018 · Primary completion Jan 31, 2025
Drug: Beta blocker · For: Myocardial Infarction
Sites: San Severo, Italy; Alessandria, Italy; Ancona, Italy · 111 sites in all
- Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 HypertensionPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01508026 · 4,161 participants · Start Jan 2012 · Primary completion Mar 2013
Drug: Nebivolol and Valsartan 1; Nebivolol and Valsartan 2 and 6 more · For: Stage 1 Hypertension; Stage 2 Hypertension
Sites: Birmingham, Alabama; Foley, Alabama; Gulf Shores, Alabama · 413 sites in all
- Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of ChronotherapyPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00295542 · 3,344 participants · Start Mar 2000 · Primary completion Apr 2009
Drug: ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan) and 2 more · For: Hypertension
Sites: Santiago de Compostela, Spain
- Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection FractionPivotal-lookingActive, not recruiting
Bispebjerg HospitalAcademic, hospital or other
NCT03778554 · 2,760 participants (planned) · Start Dec 17, 2018 · Primary completion Apr 1, 2025
Drug: Metoprolol Succinate; Bisoprolol and 2 more · For: Acute Myocardial Infarction; Non-ST Elevation Myocardial Infarction (nSTEMI); ST Elevation Myocardial Infarction
Sites: Copenhagen, Denmark
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic PatientsPivotal-lookingRecruiting
Martin HuelsmannAcademic, hospital or other
NCT02817360 · 2,400 participants (planned) · Start Feb 2016 · Primary completion Dec 2025
Drug: RAS-antagonist and beta-blocker up-to maximal dosages · For: Heart Diseases; Diabetes Mellitus, Type 2
Sites: Mödling, Austria; Graz, Austria; Linz, Austria · 21 sites in all
- Beta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection FractionPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06518694 · 1,300 participants (planned) · Start Feb 11, 2025 · Primary completion Oct 2027
Drug: Βeta-Blockers discontinued (with tapering) · For: Heart Failure
Sites: Paris, France
- A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive PatientsPivotal-lookingCompleted
Mylan Bertek PharmaceuticalsIndustry
NCT00200499 · 845 participants · Start Mar 2002
Drug: Nebivolol · For: Hypertension
Sites: Morgantown, West Virginia
- A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive PatientsPivotal-lookingCompleted
Mylan Bertek PharmaceuticalsIndustry
NCT00200460 · 825 participants · Start Sep 2001
Drug: Nebivolol · For: Hypertension
Sites: Morgantown, West Virginia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue1,332
- drug ineffective1,073
- diarrhoea1,060
- nausea1,030
- headache982
- dyspnoea936
- dizziness906
- off label use712
- pain660
- asthenia622
- blood pressure increased587
- arthralgia539
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 10 |
| 2006 | 8 |
| 2007 | 12 |
| 2008 | 77 |
| 2009 | 634 |
| 2010 | 727 |
| 2011 | 610 |
| 2012 | 821 |
| 2013 | 906 |
| 2014 | 1,056 |
| 2015 | 1,619 |
| 2016 | 1,982 |
| 2017 | 1,351 |
| 2018 | 1,643 |
| 2019 | 1,399 |
| 2020 | 1,160 |
| 2021 | 840 |
| 2022 | 917 |
| 2023 | 681 |
| 2024 | 628 |
| 2025 | 539 |
| 2026 | 373 |
Recalls
1 FDA enforcement reports for this application.
May 12, 2014 · Class II · Terminated
Failed Dissolution Specifications: One lot of product is being voluntarily recalled because dissolution test results failed to meet specification throughout the product's shelf life.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Bystolic (Nebivolol HCl)
2024 spending
$16.5M
Beneficiaries
9,360
41,207 claims
Per beneficiary
$1,759
$5.74 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $480,351,460 |
| 2021 | $415,408,373 |
| 2022 | $74,364,816 |
| 2023 | $23,909,158 |
| 2024 | $16,462,137 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis.
Kaddoura R, Madurasinghe V, Chapra A, et al. · Curr Probl Cardiol 2024 · Meta-Analysis, Systematic Review
- Beta-blockers for hypertension.
Wiysonge CS, Bradley HA, Volmink J, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
Flather MD, Shibata MC, Coats AJ, et al. · Eur Heart J 2005 · Clinical Trial, Multicenter Study
- A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients.
Qian J, Zhang M, Chen Z · Adv Ther 2024 · Systematic Review, Comparative Study
- Atrial fibrillation (acute onset).
Lip GY, Apostolakis S · BMJ Clin Evid 2014 · Systematic Review
- Beta-blockers in hypertension.
Ram CV · Am J Cardiol 2010 · Meta-Analysis, Review
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.